Diagnostic Approach to Growth Hormone Deficiency in Short Individuals

Initial Assessment

The American Academy of Pediatrics recommends determining if short stature is isolated or associated with other physical/developmental abnormalities, and whether it is proportionate or disproportionate 1
The National Institute of Health suggests documenting height (or supine length for patients <2 years) and calculating height velocity over at least 6 months, comparing to standardized growth charts 2
Assess growth potential through calculation of genetic target height based on parental heights and evaluation of epiphyseal closure via left wrist radiography, as recommended by the American College of Medical Genetics 2
Review birth measurements (weight, length, head circumference) to identify any intrauterine growth restriction, according to the Genetics in Medicine guidelines 1
Evaluate for dysmorphic features that might suggest a syndrome or chromosomal abnormality, as suggested by the American College of Medical Genetics 1

The American Academy of Pediatrics characterizes constitutional delay of growth as deceleration of growth in first 3 years, normal velocity during childhood (4-7 cm/year), delayed bone age and puberty, with final adult height within normal range 1
Familial short stature is described by the American College of Medical Genetics as early deceleration in linear growth, normal growth velocity, normal bone age and pubertal development, with final height appropriate for genetic target 1
Pathologic short stature is defined by the Genetics in Medicine guidelines as crossing of several centile lines between 3 years and late childhood/early adolescence 1

Initial screening tests should include complete blood count, comprehensive metabolic panel, thyroid function tests, as recommended by the Praxis Medical Insights 3
Bone age assessment via left wrist radiography is suggested by the National Institute of Health 2

Fundoscopic examination to rule out papilledema before initiating GH therapy is recommended by the National Institute of Health 4
For disproportionate short stature, skeletal survey should be performed to evaluate for skeletal dysplasia, according to the Genetics in Medicine guidelines 5

For girls with short stature, chromosomal analysis should be performed to rule out Turner syndrome, which is the most common pathologic diagnosis in genetic evaluations of short stature, as recommended by the Praxis Medical Insights 3
SHOX gene testing should be considered in cases of familial short stature with subtle skeletal changes or findings suggestive of dyschondrosteosis, according to the Genetics in Medicine guidelines 5
For children with chronic kidney disease, additional evaluation of renal function, metabolic status, and mineral dysregulation is necessary, as suggested by the National Institute of Health 6

Treatment should be discontinued when height velocity drops below 2 cm/year and/or when epiphyseal growth plates close, as recommended by the Praxis Medical Insights 7

Failing to distinguish between normal variants (constitutional delay, familial short stature) and pathologic causes can lead to delayed or inappropriate treatment, according to the Praxis Medical Insights 3
Missing Turner syndrome in girls with short stature, as warned by the Praxis Medical Insights 3
Overlooking the need for regular monitoring of growth velocity during treatment, as suggested by the National Institute of Health 2

The Endocrine Society recommends that a diagnosis of Growth Hormone Deficiency (GHD) be considered in children with severely low IGF-1 levels, delayed bone age, and proportionate short stature 8, 9
A severely low IGF-1 level of 18 ng/mL, which is dramatically below the age-appropriate range of 67-405 ng/mL, is a reliable marker for GH axis dysfunction, as suggested by the American Academy of Pediatrics 8, 9
The presence of delayed bone age, with a 3-year delay in this case, is characteristic of GHD and distinguishes it from familial short stature, according to the Genetics in Medicine guidelines 10, 11
Proportionate short stature, with a height of 120 cm at age 9, suggests an endocrine rather than skeletal dysplasia cause, as indicated by the American College of Medical Genetics and Genomics 10, 11

Failure to Thrive is excluded because it typically applies to infants and young children with inadequate weight gain and poor caloric intake, as defined by the American Academy of Pediatrics 12
Familial Short Stature is unlikely because it presents with normal bone age and normal growth velocity, and IGF-1 levels are typically normal, as stated by the Genetics in Medicine guidelines 11

IGF-1 is the critical discriminator, with severely low levels indicating GH axis dysfunction, as recommended by the Endocrine Society 8, 9
Bone age assessment confirms pathology, with a 3-year delay distinguishing GHD from familial short stature, according to the American Academy of Pediatrics 8, 9
Other pituitary hormones are normal, suggesting isolated GHD rather than multiple pituitary hormone deficiency, as indicated by the Endocrine Society 8, 11

If GHD is confirmed, recombinant human GH therapy at 0.045-0.05 mg/kg/day would be indicated, with the severely delayed bone age suggesting substantial remaining growth potential, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 13